ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.599,57
-0,46%
S&P 500
5.222,68
0,16%
US Dollar vs BRL
5,1568
0,37%
Bitcoin
61.350,36
0,91%
Brent Oil
82,585
0,00%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Jounce Therapeutics Inc (JNCE)

  7. Jounce Therapeutics Inc (JNCE) Notícias

JNCE

Jounce Therapeutics (JNCE)

Jounce Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:JNCE
DataHoraFonteTítuloCódigoCompanhia
14/02/202410:50Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:JNCEJounce Therapeutics Inc
15/05/202308:41Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:JNCEJounce Therapeutics Inc
05/05/202317:38Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:JNCEJounce Therapeutics Inc
05/05/202317:35Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:JNCEJounce Therapeutics Inc
05/05/202307:09Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:JNCEJounce Therapeutics Inc
04/05/202309:40Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:JNCEJounce Therapeutics Inc
04/05/202308:31Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:JNCEJounce Therapeutics Inc
04/05/202308:25Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:JNCEJounce Therapeutics Inc
04/05/202308:23Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:JNCEJounce Therapeutics Inc
04/05/202308:08Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:JNCEJounce Therapeutics Inc
03/05/202321:35GlobeNewswire Inc.Jounce Therapeutics Announces Closing of Tender OfferNASDAQ:JNCEJounce Therapeutics Inc
28/04/202315:48Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:JNCEJounce Therapeutics Inc
03/04/202308:55Edgar (US Regulatory)Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)NASDAQ:JNCEJounce Therapeutics Inc
03/04/202303:00GlobeNewswire Inc.Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plcNASDAQ:JNCEJounce Therapeutics Inc
27/03/202315:12Edgar (US Regulatory)Statement of Ownership: Solicitation (sc 14d9)NASDAQ:JNCEJounce Therapeutics Inc
27/03/202310:00GlobeNewswire Inc.Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value RightsNASDAQ:JNCEJounce Therapeutics Inc
16/03/202317:30GlobeNewswire Inc.Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian CancerNASDAQ:JNCEJounce Therapeutics Inc
14/03/202322:00GlobeNewswire Inc.Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra BiosciencesNASDAQ:JNCEJounce Therapeutics Inc
14/03/202318:01Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:JNCEJounce Therapeutics Inc
10/03/202311:24Edgar (US Regulatory)Annual Report (10-k)NASDAQ:JNCEJounce Therapeutics Inc
06/03/202318:00Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:JNCEJounce Therapeutics Inc
23/02/202318:56Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:JNCEJounce Therapeutics Inc
23/02/202304:30GlobeNewswire Inc.Redx and Jounce Announce Recommended Business CombinationNASDAQ:JNCEJounce Therapeutics Inc
22/02/202319:00GlobeNewswire Inc.Jounce Therapeutics Announces RestructuringNASDAQ:JNCEJounce Therapeutics Inc
14/02/202318:55Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:JNCEJounce Therapeutics Inc
09/01/202308:02Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:JNCEJounce Therapeutics Inc
27/12/202219:24Dow Jones NewsGilead Sciences to Acquire Remaining Rights to GS-1811 from Jounce TherapeuticsNASDAQ:JNCEJounce Therapeutics Inc
27/12/202218:30Business WireGilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce TherapeuticsNASDAQ:JNCEJounce Therapeutics Inc
27/12/202218:30GlobeNewswire Inc.Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce TherapeuticsNASDAQ:JNCEJounce Therapeutics Inc
08/12/202209:50GlobeNewswire Inc.Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO - IO) Annual CongressNASDAQ:JNCEJounce Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:JNCE

Seu Histórico Recente

AMEX
AZBO
Allianzim US Large Cap B...
USOTC
RGMP
Regnum (CE)
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados